Market Overview - China has over 140 million diabetes patients, the highest in the world, expected to rise to 174 million by 2045, creating a vast market for Continuous Glucose Monitoring (CGM) technology [1][2] - The global CGM market is projected to reach 71.8 billion yuan by 2025, with a compound annual growth rate (CAGR) of 14.49%, reaching 185.2 billion yuan by 2032 [2] Competitive Landscape - The CGM market in China is divided into two main camps: imported brands like Abbott and Dexcom dominate the market, while domestic companies like Jiuno, Kailite, and others are emerging with competitive software technology [1][3] - Abbott leads the global CGM market with a revenue of 5.76 billion USD in 2023, holding about 50% market share, followed by Dexcom with 3.62 billion USD and Medtronic with 2.26 billion USD [7] Technology and Product Development - CGM technology provides continuous blood glucose information, addressing the limitations of traditional blood glucose measurements [3][4] - Domestic CGM companies are focusing on patent protection and technological innovation, with several companies having filed hundreds of patents [8][9] - The CGM market is characterized by high technical barriers, requiring expertise in multiple disciplines such as sensor design and calibration algorithms [8] Market Penetration and Growth Potential - The penetration rate of CGM in China is currently low, with projections indicating significant growth by 2030: 38% for type 1 diabetes, 13.4% for type 2 diabetes, and 1% for gestational diabetes [9] - The market for continuous glucose monitoring systems in China is estimated to grow from 1.7 billion yuan in 2020 to 17.9 billion yuan by 2030 [9] Challenges and Future Trends - Despite the advantages of CGM, its adoption in hospitals is slow, and it is primarily used as an auxiliary tool for blood glucose management [10] - Integrated Continuous Glucose Monitoring (iCGM) is emerging as a more accurate alternative, capable of connecting with IoT and AI for better diabetes management [11] - Effective data sharing between CGM devices and hospital systems remains a challenge, necessitating collaboration for improved patient management [11][12]